Pliant Therapeutics reports Q2 FY25 financial results, Phase 1 oncology trial on track.

• Pliant Therapeutics reports Q2 2025 financial results • BEACON-IPF close out activities continue • Workforce and operational realignment largely complete • Phase 1 oncology trial on track to deliver data by year-end • Company maintains core capabilities for next steps

Pliant Therapeutics, Inc. (NASDAQ: PLRX) has announced its second-quarter 2025 financial results, detailing the company's progress in its clinical trials and operational realignment efforts. The company reported a net loss of $43.3 million for the quarter, down from $55.9 million in the same period last year. This decrease was primarily attributed to the discontinuation of the BEACON-IPF Phase 2b/3 clinical trial and personnel-related cost reductions resulting from a strategic restructuring of its workforce [3].

The company also provided an update on its ongoing clinical trials. The Phase 1 oncology trial of PLN-101095, an oral, small molecule, dual selective inhibitor of αvβ8 and αvβ1 integrins, is on track to deliver initial data by the end of 2025. This trial is being conducted in patients with solid tumors that are resistant to immune checkpoint inhibitors [3].

Pliant Therapeutics has completed its workforce and operational realignment, which was largely focused on closing out activities related to the BEACON-IPF trial. The company maintains a core clinical and regulatory development organization to support its advanced trials. Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer of Pliant, stated, "We remain committed to delivering shareholder value and look forward to providing updates in the future" [3].

Institutional investors continue to show interest in Pliant Therapeutics. Several major investors, including Invesco Ltd., AQR Capital Management LLC, Jane Street Group LLC, Royal Bank of Canada, and Goldman Sachs Group Inc., have increased their stakes in the company's stock during the first quarter of 2025 [1]. This increased interest may reflect confidence in the company's pipeline and operational changes.

The company's stock has seen some price movement in recent trading sessions. On Friday, July 5th, Pliant Therapeutics stock traded up $0.12, reaching $1.58, with a trading volume of 1,475,751 shares compared to its average volume of 1,107,925. The stock has a market cap of $97.00 million, a PE ratio of -0.44, and a beta of 1.42 [1].

Analysts expect Pliant Therapeutics to post a loss of $0.70 per share for the quarter, with a current average analyst rating of "hold." The mean earnings estimate of analysts was unchanged in the last three months [2]. The Wall Street median 12-month price target for Pliant Therapeutics is $3.00, about 51.3% above its last closing price of $1.46 [2].

In conclusion, Pliant Therapeutics has reported its Q2 2025 financial results, showing a decrease in net loss due to the discontinuation of the BEACON-IPF trial and workforce restructuring. The company's Phase 1 oncology trial is on track to deliver data by the end of 2025, and it maintains core capabilities for future steps. Institutional investors have shown continued interest in the company's stock.

References:
[1] https://www.marketbeat.com/instant-alerts/pliant-therapeutics-plrx-expected-to-announce-earnings-on-wednesday-2025-07-30/
[2] https://www.tradingview.com/news/reuters.com,2025:newsml_L8N3TT19L:0-pliant-therapeutics-inc-expected-to-post-a-loss-of-70-cents-a-share-earnings-preview/
[3] https://www.globenewswire.com/news-release/2025/08/07/3129637/0/en/Pliant-Therapeutics-Provides-Corporate-Update-and-Reports-Second-Quarter-2025-Financial-Results.html